Wondering if anyone has any insight as to where this is at, right now. I was on regulations.gov, and saw comments from Bill Sardi and Jarrow (amongst many others). Very good.
It sounds like the draft guidance issue has been given additional time to the public (Dec?) to enter comments. Also, does anyone know if there are any pharmaceutical companies that are directly involved in trying to seek these FDA and Durbin moves, through Freedom of Information Act? -Ken
